BAY-299 disrupts the function of proteins that recognize and bind specific epigenetic marks, affecting the interpretation of epigenetic signals. It targets BRPF1 BD, BRPF2 BD, BRPF3 BD, BRPF1 BD, and TAF1L BD2.
BAY-299 can be utilized to explore the inhibition of BRD4, a key BET bromodomain protein, in relation to gene transcription and cancer.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.